Natco Pharma Ltd. — Earnings Release 2019

Nov 5, 2018

==> picture [480 x 49] intentionally omitted <==

November 5, 2018

Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Dalal Sreet, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai 400 001 Bandra (E) Mumbai 400 051

Scrip Code: 524816 Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

==> picture [106 x 23] intentionally omitted <==

M. Adinarayana Company Secretary & Vice President (Legal and Corp Affairs

==> picture [451 x 46] intentionally omitted <==

Ref:PR/ 8 /2018

Press Release

Hyderabad, 5[nd] November, 2018

NATCO records INR 583.40 Crores consolidated revenue and INR 181.50 Crore of profit, after tax, for the Second Quarter, FY2018-19

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 583.50 Crore for the second quarter ended on 30[th] September, 2018, as against INR 432.20 Crore for the same period last year, reflecting a growth of 35%. The net profit for the period, on a consolidated basis, was INR 181.60 Crores as against INR 84.40 Crore same period last year, showing a growth of 115%.

During the quarter, the company has witnessed growth in the formulations business- both domestic and exports. The breakup of revenues has Formulations domestic Rs. 193.87 crores, Formulation exports including profit share/service income Rs. 247.81 crores, API revenues Rs. 66.81 crores, other operating / other income Rs.53.61 crores and subsidiary revenues Rs. 21.40 crores for quarter ended 30[th] September 2018.

---

Forwarded for favor of publication For NATCO Pharma Limited

==> picture [106 x 22] intentionally omitted <==

M. Adinarayana Company Secretary & Vice President (Legal and Corp Affairs)